Zobrazeno 1 - 10
of 575
pro vyhledávání: '"Shlomo, Melmed"'
Autor:
Tugce Apaydin, Svetlana Zonis, Cuiqi Zhou, Christian Wong Valencia, Robert Barrett, Ger J. Strous, Jan A. Mol, Vera Chesnokova, Shlomo Melmed
Publikováno v:
iScience, Vol 26, Iss 11, Pp 108117- (2023)
Summary: DNA damage repair (DDR) is mediated by phosphorylating effectors ATM kinase, CHK2, p53, and γH2AX. We showed earlier that GH suppresses DDR by suppressing pATM, resulting in DNA damage accumulation. Here, we show GH acting through GH recept
Externí odkaz:
https://doaj.org/article/b5f82b10752d46ddb107f6fd1578f0a5
Publikováno v:
Stem Cell Research, Vol 69, Iss , Pp 103124- (2023)
MEN1, an autosomal dominant disorder caused by mutations in the tumor suppressor gene MEN1, manifests with co-occurrence of multiple endocrine/neuroendocrine neoplasms. An iPSC line derived from an index patient carrying the mutation c.1273C>T (p.Arg
Externí odkaz:
https://doaj.org/article/c4d2d0c3952049978d48f9c3c72fccbf
Autor:
Artak Labadzhyan, Shlomo Melmed
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
Molecular therapeutic targets in growth hormone (GH)-secreting adenomas range from well-characterized surface receptors that recognize approved drugs, to surface and intracellular markers that are potential candidates for new drug development. Curren
Externí odkaz:
https://doaj.org/article/90e2ef612ef249fe875b1738791ef0ca
Autor:
Vera Chesnokova, Shlomo Melmed
Publikováno v:
Archives of Endocrinology and Metabolism, Vol 63, Iss 6, Pp 568-575 (2020)
ABSTRACT Tumor development is a multistep process whereby local mechanisms enable somatic mutations during preneoplastic stages. Once a tumor develops, it becomes a complex organ composed of multiple cell types. Interactions between malignant and non
Externí odkaz:
https://doaj.org/article/1f25d4881b094ad5870d904249b7c2c0
Autor:
Vera Chesnokova, Svetlana Zonis, Athanasia Apostolou, Hannah Q. Estrada, Simon Knott, Kolja Wawrowsky, Kathrin Michelsen, Anat Ben-Shlomo, Robert Barrett, Vera Gorbunova, Katia Karalis, Shlomo Melmed
Publikováno v:
Cell Reports, Vol 37, Iss 11, Pp 110068- (2021)
Summary: Microenvironmental factors modulating age-related DNA damage are unclear. Non-pituitary growth hormone (npGH) is induced in human colon, non-transformed human colon cells, and fibroblasts, and in 3-dimensional intestinal organoids with age-a
Externí odkaz:
https://doaj.org/article/8ce93d02002e4ca285974a19e64c5805
Publikováno v:
The Lancet Diabetes & Endocrinology. 10:804-826
Growth hormone-secreting pituitary adenomas that cause acromegaly arise as monoclonal expansions of differentiated somatotroph cells and are usually sporadic. They are almost invariably benign, yet they can be locally invasive and show progressive gr
Autor:
Yujuan Gui, Mélanie H. Thomas, Pierre Garcia, Mona Karout, Rashi Halder, Alessandro Michelucci, Heike Kollmus, Cuiqi Zhou, Shlomo Melmed, Klaus Schughart, Rudi Balling, Michel Mittelbronn, Joseph H. Nadeau, Robert W. Williams, Thomas Sauter, Manuel Buttini, Lasse Sinkkonen
Publikováno v:
Frontiers in Genetics, Vol 11 (2020)
Dopaminergic neurons in the midbrain are of particular interest due to their role in diseases such as Parkinson’s disease and schizophrenia. Genetic variation between individuals can affect the integrity and function of dopaminergic neurons but the
Externí odkaz:
https://doaj.org/article/54d054775e744ce8a53a0661038a6a2d
Autor:
Ning-Ai Liu, Anat Ben-Shlomo, John D Carmichael, Christina Wang, Ronald S Swerdloff, Anthony P Heaney, Garni Barkhoudarian, Daniel Kelly, Mazen Noureddin, Lin Lu, Manish Desai, Yana Stolyarov, Kevin Yuen, Adam N Mamelak, James Mirocha, Mourad Tighiouart, Shlomo Melmed
Publikováno v:
J Clin Endocrinol Metab
Context Preclinical studies show seliciclib (R-roscovitine) suppresses neoplastic corticotroph proliferation and pituitary adrenocorticotrophic hormone (ACTH) production. Objective To evaluate seliciclib as an effective pituitary-targeting treatment
Autor:
Andrea Giustina, Melin Meliha Uygur, Stefano Frara, Ariel Barkan, Nienke R. Biermasz, Philippe Chanson, Pamela U. Freda, Monica Gadelha, Ursula B. Kaiser, Steven W.J. Lamberts, Edward Laws, Lisa B. Nachtigall, Vera Popovic, Martin Reincke, Christian Strasburger, Aart J. van der Lely, John A.H. Wass, Shlomo Melmed, Felipe F. Casanueva
Purpose The Pituitary Society established the concept and mostly qualitative parameters for defining uniform criteria for pituitary tumor centers of excellence (PTCOEs) based on expert consensus. To validate those previously proposed criteria through
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbcf61d9920e0c29df44f8e97d62a8a2
https://doi.org/10.21203/rs.3.rs-2906998/v1
https://doi.org/10.21203/rs.3.rs-2906998/v1
Autor:
Hans-Jürgen Wester, Annamaria Vezzani, Giovanni Tulipano, John E. Taylor, Stefan Schulz, Agnes Schonbrunn, Herbert Schmid, Marcus Schindler, Jean-Claude Reubi, Terry Reisine, Yogesh C. Patel, Anne-Marie O'Carroll, Wolfgang Meyerhof, Shlomo Melmed, Amelie Lupp, Hans-Jürgen Kreienkamp, Patrick P. A. Humphrey, Daniel Hoyer, Leo Hofland, Rebecca Hills, Anthony Harmar, Wasyl Feniuk, Jacques Epelbaum, Pascal Dournaud, Micheal Culler, Zsolt Csaba, Justo P. Castaño, Corinne Bosquet
Publikováno v:
IUPHAR/BPS Guide to Pharmacology CITE. 2023
Somatostatin (somatotropin release inhibiting factor) is an abundant neuropeptide, which acts on five subtypes of somatostatin receptor (SST1-SST5; nomenclature as agreed by the NC-IUPHAR Subcommittee on Somatostatin Receptors [98]). Activation of th